BioCardia (BCDA)

3.83 +0.08 (2.13%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Form 8-K BioCardia, Inc. For: Jan 05 January 11, 2021 8:31 AM - SEC Filing Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors January 11, 2021 8:30 AM - Globe NewsWire Form 4 BioCardia, Inc. For: Dec 31 Filed by: STERTZER SIMON H January 5, 2021 9:55 PM - SEC Filing Form 4 BioCardia, Inc. For: Dec 31 Filed by: KRASNO RICHARD M January 5, 2021 9:55 PM - SEC Filing Form 4 BioCardia, Inc. For: Dec 31 Filed by: MOYES JAY M January 5, 2021 9:54 PM - SEC Filing Form 4 BioCardia, Inc. For: Dec 31 Filed by: Allen Jim L. January 5, 2021 9:54 PM - SEC Filing Form 4 BioCardia, Inc. For: Dec 31 Filed by: Blank Andrew Scott January 5, 2021 9:53 PM - SEC Filing Form 4 BioCardia, Inc. For: Dec 31 Filed by: PFENNIGER RICHARD C JR January 5, 2021 9:53 PM - SEC Filing BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies December 30, 2020 8:30 AM - Globe NewsWire Form 8-K BioCardia, Inc. For: Dec 22 December 28, 2020 4:55 PM - SEC Filing BioCardia (BCDA) Reports Positive DSMB Review & Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed December 17, 2020 8:33 AM - StreetInsider BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed December 17, 2020 8:30 AM - Globe NewsWire BioCardia (BCDA) Prices 2.039M Share Registered Direct Offering at $5.15/Sh December 16, 2020 8:34 AM - StreetInsider BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules December 16, 2020 8:30 AM - Globe NewsWire BioCardia (BCDA) Prices 1.79M Share Registered Direct Offering at $4.75/Sh December 15, 2020 6:09 AM - StreetInsider BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Revised] December 15, 2020 1:21 AM - Globe NewsWire BioCardia (BCDA) Announces $8.5 Million Registered Direct Offering Priced At at $4.75/sh December 14, 2020 3:24 PM - StreetInsider BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules December 14, 2020 3:21 PM - Globe NewsWire BioCardia (BCDA) Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial December 14, 2020 8:07 AM - StreetInsider BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial December 14, 2020 8:00 AM - Globe NewsWire BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems December 1, 2020 7:00 AM - Globe NewsWire BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights November 10, 2020 7:00 AM - Globe NewsWire BioCardia (BCDA) Publishes Peer-reviewed Initial Data from Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Funct October 26, 2020 7:36 AM - StreetInsider Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function October 26, 2020 7:30 AM - Globe NewsWire Full Article List